Immunotherapy Goes Viral. Cell Sept. 7, 2017 (Vol. 170, Issue 6)
2,605 views · Published 7 September 2017 · 2:59 · Indexed 14 November 2026
Channel: Cell Press · 2017 · Science & Technology
Checkpoint blockade therapy is changing the face of cancer treatment, but not every patient responds to immunotherapy and there is urgent need to identify ways to improve its efficacy. In this video abstract, Toni Ribas and his colleagues report the initial results of a clinical trial testing the benefit of combining checkpoint blockade therapy and oncolytic virotherapy in melanoma patients. Check out the paper at: http://www.cell.com/cell/fulltext/S0092-8674(17)30952-2. Antoni Ribas, Reinhard Dummer, Igor Puzanov, Ari VanderWalde, Robert H.I. Andtbacka, Olivier Michielin, Anthony J. Olszanski, Josep Malvehy, Jonathan Cebon, Eugenio Fernandez, John M. Kirkwood, Thomas F. Gajewski, Lisa Chen, Kevin S. Gorski, Abraham A. Anderson, Scott J. Diede, Michael E. Lassman, Jennifer Gansert, F. Stephen Hodi, and Georgina V. Long (2017). Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell 170. And read more great research at http://www.cell.com/cell/home.
More from this channel
-
2:55
Chromatin shapes the mitotic spindle
-
5:14
The architecture of adaptation
-
4:14
Wnts come in small packages
-
6:09
Helicases Find Their Way
-
3:16
Fighting Mosquito-Borne Infections
-
4:29
Leaving Trash with Moms Keeps Daughters Young
-
4:07
Feedback Control of Vocal Learning
-
4:22
DISC1 knockdown leads to behavioral deficits